echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Urinary System > Consensus Points of Chinese Experts on Prostate Cancer Screening (2021 Edition)

    Consensus Points of Chinese Experts on Prostate Cancer Screening (2021 Edition)

    • Last Update: 2021-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, the incidence of prostate cancer in China has shown a significant upward trend, and it is gradually becoming an important disease affecting the health of middle-aged and elderly men in China
    .

    Data from multi-center studies in China show that only one-third of newly diagnosed prostate cancer patients are clinically localized prostate cancer, and most patients are already in the middle and advanced stages when they are first diagnosed.
    As a result, the overall prognosis of Chinese prostate cancer patients is far worse than that of Western developed countries

    .

    "Early screening, early diagnosis, and early treatment" is one of the effective methods to improve the 5-year survival rate of cancer patients
    .

    Studies have shown that in countries that implement prostate cancer screening strategies, such as Japan, the 5-year survival rate of prostate cancer patients has increased rapidly, with an average annual increase of about 11.
    7%, and the 5-year survival rate has reached 93.
    0%, while China’s annual increase is only 3.
    7%, 5 The annual survival rate is only 69.
    2%

    .

    Therefore, screening, early diagnosis and treatment of high-risk groups are effective means to improve the overall survival rate of Chinese prostate cancer patients
    .

    The purpose and significance of the consensus on prostate cancer screening: increase the detection rate of prostate cancer in high-risk groups and detect early prostate cancer
    .

    Reduce the prostate cancer mortality of the screening population without affecting the quality of life of the screening population
    .

    Prostate cancer screening methods: 1.
    It is recommended to perform regular serum PSA testing; 2.
    It is not recommended to use PCA3 testing, p2PSA testing, 4Kscore, prostate health index, MRI examination, etc.
    as routine methods of prostate cancer screening; 3.
    Carry out screening activities At the time, the subjects’ serum samples can be collected and stored centrally and then brought back to the hospital for uniform PSA testing, or a portable PSA testing instrument can be used for rapid testing (microfluidic technology, fluorescence immunochromatography, etc.
    )

    .

    It should be noted that the results of the rapid PSA test are only used as a reference for initial screening, not as a basis for disease diagnosis.
    Subjects need to be referred to the hospital for retesting and confirmation of PSA

    .

    Prostate cancer screening population: 1.
    Perform prostate cancer screening based on serum PSA test for men who are in good physical condition and have a life expectancy of more than 10 years; 2.
    Serum PSA test is performed every 2 years, according to the age of the subject And physical conditions determine the termination time of PSA testing; 3.
    Serum PSA testing should be carried out as soon as possible for people at high risk of prostate cancer.
    High-risk groups include: men aged >50 years; men aged >45 years with a family history of prostate cancer; age> Males with PSA>1 μg/L at 40 years old; males with BRCA2 gene mutation and age>40 years old

    .

    Follow-up after PSA screening: PSA≥4μg/L was defined as an abnormal value
    .

    When the subject’s PSA is less than 4 μg/L, it is recommended to follow up once every two years; when the subject’s PSA is ≥ 4 μg/L, the subject or family members should be notified in time, and the subject is advised to switch Go to the hospital for further diagnosis, treatment and follow-up
    .

      Prostate cancer screening pathway PSA abnormal population referral pathway source: Chinese Anti-Cancer Association Urinary and Male Reproductive System Tumor Professional Committee Prostate Cancer Group.
    Chinese Expert Consensus on Prostate Cancer Screening (2021 Edition)[J].
    Chinese Journal of Cancer, 2021, 31(5): 435-440.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.